Effects of Glibenclamide and Glimepiride Compared in Type II DM Patients in Accordance with Lipid Parameters, ESF and Glycated Haemoglobin

Abstract

The population of Indian adults suffering from diabetes is expected to increase threefold, from 19.4 million in 1995 to 57.2 million in 2025. The objective of the study was to evaluate the efficacy and safety of antidiabetic drug and to find out their cardio protective action in patients with diabetes mellitus. In all, 60 patients who were newly diagnosed with Type II diabetes mellitus or who were already on treatment for Type II diabetes mellitus were enrolled in our study. The study was conducted on patients suffering from Type II diabetes mellitus for a period of 6 months from December 2011 to June 2012. These were patients attending the Medical and Surgical OPD’s of Maharajah’s Institute of Medical Sciences (MIMS) Hospital, Nellimarla, Vizianagaram district, Andhra Pradesh. Estimations of Hb%, FBS, HbA1C, Lipid Profile, ECG and Ejection Systolic Fraction (ESF) were done and compared, where HbA1C concentration was lower in the glimepiride group. Significant reduction in the total cholesterol, serum triglyceride and LDL cholesterol was observed in the Glimepiride + Metformin combination. It also increased the HDL cholesterol levels which were not observed with Glibenclamide + Metformin for the study period of 12 weeks. Thus, the Glimepiride/Metformin combination may be considered to be a better combination in patients with increased lipid parameters in comparison with Glibenclamide/Metformin combination in patients with Type II diabetes.